"10.1371_journal.pone.0112758","plos one","2014-11-14T00:00:00Z","Elisabet Matas; Laura Bau; María Martínez-Iniesta; Lucía Romero-Pinel; M Alba Mañé; Álvaro Cobo-Calvo; Sergio Martínez-Yélamos","Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, LHospitalet de Llobregat, Barcelona, Spain; Translational Research Laboratory, Institut Català dOncologia- IDIBELL, LHospitalet de Llobregat, Barcelona, Spain; Department of Neurology, Joan XXIII University Hospital, Universitat Rovira I Virgili, Tarragona, Spain","Conceived and designed the experiments: EM MMI SMY. Performed the experiments: EM LB MMI LRP MAM ACC. Analyzed the data: EM MMI SMY. Contributed reagents/materials/analysis tools: EM MMI SMY. Wrote the paper: EM LB MMI LRP MAM ACC SMY.","The authors have read the journals policy and have the following competing interests: E. Matas received honoraria from speaking engagements from Biogen, Teva and Merck Serono; research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. L. Bau received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. M. Martínez-Iniesta reports no disclosures. L. Romero-Pinel received honoraria from speaking engagements from Biogen, Teva and Merck Serono; research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. M.A. Mañé received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. A. Cobo-Calvo received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. S. Martínez-Yélamos received honoraria from speaking engagements, served on a scientific advisory board, collaborates as a consultant and scientific communications and received funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering Pharma. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","11","Elisabet Matas","EM",7,TRUE,3,6,3,7,TRUE,TRUE,TRUE,1,"6",FALSE
